- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | FDA grants RMAT designation to Taysha's Rett syndrome gene therapy | ||
| Fr | Lexicon plans another bid for Zynquista in type 1 diabetes | ||
| Fr | ESCMID 2024: Advances in drug resistance testing | ||
| Fr | NHS to provide Pfizer's Voxelotor to treat sickle cell disease | ||
| Fr | BridgeBio Oncology Therapeutics launches with $200m funding | ||
| Fr | Optimisation in operations: from theory to practice | ||
| Fr | Moderna reports $1.2bn net loss in Q1 2024 | ||
| Fr | ImmunityBio partners with Serum Institute for BCG vaccines | ||
| 02.05. | ESCMID 2024: Drug resistance in fungi - a growing issue | ||
| 02.05. | Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1 | ||
| 02.05. | Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio | ||
| 02.05. | Biotechs face upward battle with recruiting patients on obesity trials | ||
| 02.05. | Emergent cuts 300 jobs and shuts down two facilities in cost-cutting drive | ||
| 02.05. | M&A revival with a 71% increase in billion-dollar transactions in Q1 2024 | ||
| 02.05. | Janssen-Cilag seeks expanded EMA approval for TREMFYA | ||
| 02.05. | Xyphos and Poseida to develop allogeneic cell therapies for cancer | ||
| 02.05. | FDA approves Boehringer Ingelheim's Cyltezo for inflammatory ailments | ||
| 02.05. | Pfizer's reported net income declines 44% in Q1 2024 | ||
| 02.05. | The top pharmaceutical companies by R&D expenditure | ||
| 01.05. | AstraZeneca admits Covid-19 vaccine may cause blood clots in "very rare" cases | ||
| 01.05. | Neurocrine bags FDA approval for new 'sprinkle' Ingrezza formulation | ||
| 01.05. | Janssen adopts J&J name as part of global rebranding effort | ||
| 01.05. | Replay wins IND clearance for PRAME T cell cancer therapy | ||
| 01.05. | ePRO vs eCOA: Understanding the nuances in clinical trials | ||
| 01.05. | Roche's VABYSMO has successful Q1 sales despite Regeneron and Bayer's EYLEA HD launch |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
